END-STAGE HEART FAILURE REQUIRING VENTRICULAR ASSIST DEVICE OR ORTHOTOPIC HEART TRANSPLANTATION IN ANTHRACYCLINE-INDUCED CARDIAC TOXICITY

2015 ◽  
Vol 31 (10) ◽  
pp. S139-S140
Author(s):  
G.R. Thomas ◽  
M.A. McDonald ◽  
H.J. Ross ◽  
D.H. Delgado ◽  
F. Billia ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Ventricular Assist Device ◽  
Cardiac Toxicity ◽  
Orthotopic Heart Transplantation ◽  
Assist Device ◽  
Ventricular Assist ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals Heart Transplantation After Ventricular Assist Device Therapy: Benefits, Risks, and Outcomes

2020 ◽  
Vol 24 (1) ◽  
pp. 9-23 ◽  
Author(s):  
Nirvik Pal ◽  
Samuel H. Gay ◽  
Charles G. Boland ◽  
Aaron C. Lim
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Wait List ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
End Stage Heart Failure ◽  
End Stage

Heart transplantation is an established treatment for end-stage heart failure. Due to the increase in demand and persistent scarcity of organ, mechanical circulatory devices have played a major role in therapy for advanced heart failure. Usage of left ventricular assist device (LVAD) has gone up from 6% in 2006 to 43% in 2013 as per the United Network of Organ Sharing database. Majority of patients presenting for a heart transplantation are often bridged with an assist device prior for management of heart failure while on wait-list. On one hand, it is well established that LVADs improve survival on wait-list; on the other hand, the effect of LVAD on morbidity and survival after a heart transplantation is still unclear. In this article, we review the available literature and attempt to infer the outcomes given the risks and benefits of heart transplantation with prior LVAD patients.

Sign in / Sign up

Export Citation Format

Share Document